GW Pharmaceuticals Announces Proposed Public Offering of ADSs
October 01, 2018 16:01 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering,...
GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce the DEA has Rescheduled EPIDIOLEX® (cannabidiol) Oral Solution to Schedule V
September 27, 2018 09:27 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering,...
GW Pharmaceuticals presents latest cannabidiol oral solution (CBD) data at the 13th European Congress of Epileptology
August 28, 2018 02:00 ET
|
GW Pharmaceuticals plc
VIENNA, Austria, Aug. 28, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the development and commercialization of cannabinoid...
GW Pharmaceuticals plc Reports Fiscal Third Quarter 2018 Financial Results and Operational Progress
August 07, 2018 16:01 ET
|
GW Pharmaceuticals plc
- Epidiolex® (cannabidiol) oral solution approved by FDA and on track to be launched in Fall -- Conference call today at 4:30 p.m. ET - LONDON and CARLSBAD, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE)...
GW Pharmaceuticals to Report Third Quarter Financial Results and Host Conference Call on 7 August, 2018
July 23, 2018 16:00 ET
|
GW Pharmaceuticals plc
LONDON, July 23, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel...
GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce FDA Approval of EPIDIOLEX® (cannabidiol) oral solution – the First Plant-derived Cannabinoid Prescription Medicine
June 25, 2018 12:57 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering,...
GW Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
June 06, 2018 13:19 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., June 06, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Cannabidiol Oral Solution in Lennox-Gastaut Syndrome
May 16, 2018 17:00 ET
|
GW Pharmaceuticals plc
– First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Epidiolex® (cannabidiol oral solution) in Lennox-Gastaut Syndrome
May 16, 2018 17:00 ET
|
GW Pharmaceuticals plc
– First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset...
GW Pharmaceuticals plc Reports Fiscal Second Quarter 2018 Financial Results and Operational Progress
May 08, 2018 16:00 ET
|
GW Pharmaceuticals plc
- Positive unanimous vote at Epidiolex® (cannabidiol) FDA Advisory Committee meeting -- NDA PDUFA goal date scheduled for June 27, 2018 -- Conference call today at 4:30 p.m. EST - LONDON and...